North America HPV Testing And Pap Test Market

North America HPV Testing and Pap Test Market Size (2024 to 2029)

The HPV Testing and Pap Test Market size in North America was around USD 2.34 billion in 2024. It is expected to grow at a CAGR of 6.9% to reach USD 3.34 billion by 2029. It captures 50% of the global market. It is also the fastest-growing market worldwide.

According to the WHO, cervical cancer is the fourth most common cancer in women. An estimated 6,28,924 new cases of the cervix were diagnosed in 2020, so the growing number of patients will drive overall market growth. The Centers for Disease Control (CDC) predicts that approximately 78 million people are currently infected with HPV in the United States, and it is about 14 million people in the United States are infected with new HPV infections each year. Therefore, the increasing number of cervical cancer cases has driven the market demand for HPV and Pap tests.

These tests include the microscopic observation of the samples. However, these tests cannot detect all of the genotypes that cause HPV infections and can also lead to a significant number of false negatives.

This research report on the North America HPV Testing and Pap Test Market has been segmented and sub-segmented into the following categories:

• By Test Type: HPV Testing, Follow-up HPV Testing, HPV Primary Testing, Co-Testing and PAP Test
• By Application: Vaginal Cancer Screening and Cervical Cancer Screening
• By End-users: Laboratories, Hospitals, Physicians, Offices and Clinics
• By Country: The United States, Canada, and Rest of North America

Regionally, in 2023, North America commanded the market in terms of revenue because of the continual introduction of innovative technologies to improve patient care and diagnosis. Additionally, the high number of positive cases being detected, coupled with the increasing death toll (i.e., 2.6 in 1,00,000), has forced the government to carry out awareness programs regarding the early diagnosis and treatment of cervical cancer, which is a significant factor for the large market share.

About 2.4 million people dollars should be added jobs in the industry during this period in the United States. The highest median annual salary was recorded at USD 214,000 or more for physicians and surgeons in 2020. Similarly, the median yearly salary recorded for other health professions in June 2019 was USD 172,380 for dentists, USD 149,370 for physicians, USD 97,147 for occupational therapists, and USD 31,413 for various health care support professions, such as home health aides and medical transcriptionists. According to statistics released by the United States Bureau of Labor Statistics, the employment rate of various health professionals in the health sector is expected to increase by 15% between 2024 and 2029. Increased demand for services and facilities Medical Healthcare in North America region is estimated to significantly impact the North American Pap test and HPV test market growth in the area between 2024 and 2029. 

Besides, the increase in spending on the population of countries like the United States and Canada further stimulates this industry's growth. Per capita purchasing power parity (PPP) -based health expenditure in the United States has increased significantly from $ 9,272.27 in 2018 to $ 10,235.18 in 2020, while it increased from USD 4,832.83 USD in 2018 to USD 5,151 in 2020 in Canada. According to the World Health Organization, spending on personal health care in the United States, reported by the Centers for Disease Control and Prevention, is expected to increase by a 4.8% annual percentage change in percentage over the period 2010-2020, with spending a total of $ 2.237 billion in 2010, which rose to 3.231 billion USD in 2020. It can be attributed to the high demand for new drugs.

Some of the companies dominating the North America HPV Testing and PAP Test Market profiled in this report are Abbott Laboratories, Qiagen N.V., Roche Diagnostics, Hologic, Inc., Becton, Dickinson and Company, Quest Diagnostics, Onco Health Corporation, Seegene, Inc., Femasys Inc., and Arbor Vita Corporation.